ArticleInternational journal of surgery (London, England)2026
Single-cell mapping of tumor-driven macrophage reprogramming via ETV4-MC1R underlies immunotherapy resistance in colorectal cancer.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunotherapy resistance remains a major clinical challenge in advanced microsatellite instability-high (MSI-H) colorectal cancer (CRC), and the underlying gene regulatory networks (GRNs) distinguishing PD-1-resistant from PD-1-sensitive tumors are poorly defined. Methods: We performed single-cell RNA sequencing on tumor samples from three PD-1-resistant and three PD-1-sensitive MSI-H metastatic CRC patients. Resistance-associated transcription factors were identified by integrating machine learning-based prognostic modeling with GRN reconstruction. Bioinformatic findings were functionally validated using dual-luciferase reporter assays, chromatin immunoprecipitation, and Results: Several transcriptional regulators were highly active in resistant tumors, among which the transcription factor ETV4 was markedly upregulated in malignant epithelial cells and played a central role. A prognostic model based on ETV4 downstream target genes effectively stratified CRC into subtypes with distinct outcomes. Transcriptome-wide correlation analysis revealed a strong positive association between ETV4 expression and macrophage markers. Mechanistically, we identified MC1R as a critical downstream target of ETV4 mediating resistance. Functional assays confirmed direct binding and activation of the MC1R promoter by ETV4. Co-culture experiments demonstrated that ETV4-high CRC cells promoted macrophage polarization toward an immunosuppressive M2 phenotype via the MC1R pathway. Conclusion: This study reconstructs the regulatory network underlying PD-1 resistance in CRC at single-cell resolution and reveals a novel tumor-intrinsic ETV4-MC1R signaling axis that drives M2 macrophage polarization and immune evasion. Targeting this pathway presents a promising combination strategy to overcome immunotherapy resistance in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.